BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 34298741)

  • 21. Differential diagnoses and the mutational landscape of myelodysplastic/myeloproliferative neoplasm with neutrophilia: A case report.
    Strasser B; Grünberger M; Steindl R; Heibl S; Thaler J; Haushofer A
    Mol Clin Oncol; 2023 Aug; 19(2):62. PubMed ID: 37456801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myelodysplastic/myeloproliferative neoplasms.
    Hyjek E; Vardiman JW
    Semin Diagn Pathol; 2011 Nov; 28(4):283-97. PubMed ID: 22195406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.
    Orazi A; Germing U
    Leukemia; 2008 Jul; 22(7):1308-19. PubMed ID: 18480833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Classification of myeloid leukemias].
    Kuriyama K
    Nihon Rinsho; 2009 Oct; 67(10):1853-62. PubMed ID: 19860179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The implications of revised WHO classification (2008) of chronic myeloid neoplasms.
    Găman M; Vlădăreanu AM; Radesi S
    Rom J Intern Med; 2011; 49(1):25-30. PubMed ID: 22026249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
    Gerds AT; Gotlib J; Bose P; Deininger MW; Dunbar A; Elshoury A; George TI; Gojo I; Gundabolu K; Hexner E; Hobbs G; Jain T; Jamieson C; Kuykendall AT; McMahon B; Mohan SR; Oehler V; Oh S; Pardanani A; Podoltsev N; Ranheim E; Rein L; Salit R; Snyder DS; Stein BL; Talpaz M; Thota S; Vachhani P; Wadleigh M; Walsh K; Ward DC; Bergman MA; Sundar H
    J Natl Compr Canc Netw; 2020 Sep; 18(9):1248-1269. PubMed ID: 32886902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.
    Montenegro-Garreaud X; Miranda RN; Reynolds A; Tang G; Wang SA; Yabe M; Wang W; Fang L; Bueso-Ramos CE; Lin P; Medeiros LJ; Lu X
    Hum Pathol; 2017 Jul; 65():147-156. PubMed ID: 28551329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
    Tiu RV; Sekeres MA
    Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib.
    Yao S; Na L; Liangding H
    Ann Hematol; 2024 Jun; ():. PubMed ID: 38888615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
    Liu YC; Illar GM; Bailey NG
    J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A rare atypical chronic myeloid leukemia BCR-ABL1 negative with concomitant
    Gao T; Yu C; Xia S; Liang T; Gu X; Liu Z
    Ther Adv Hematol; 2020; 11():2040620720927105. PubMed ID: 32782768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atypical myeloproliferative disorders: diagnosis and management.
    Tefferi A; Elliott MA; Pardanani A
    Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
    Tovar-Bobadilla JL; Ortiz-Hidalgo C
    Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Myelodysplastic/myeloproliferative neoplasm: a histopathological review].
    Kayano H
    Rinsho Ketsueki; 2018; 59(10):2084-2088. PubMed ID: 30305512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and Molecular Approach to Adult-Onset, Neoplastic Monocytosis.
    Shallis RM; Siddon AJ; Zeidan AM
    Curr Hematol Malig Rep; 2021 Jun; 16(3):276-285. PubMed ID: 33890194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
    Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
    Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms.
    Sadigh S; Hasserjian RP; Hobbs G
    Curr Opin Hematol; 2020 Mar; 27(2):122-127. PubMed ID: 31904665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis.
    Wan Z; Han B
    Front Oncol; 2020; 10():579221. PubMed ID: 33117717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
    Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
    Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current diagnosis of myeloproliferative neoplasms (2008 WHO classification)].
    Frenkel' MA
    Klin Lab Diagn; 2011 Jan; (1):43-9. PubMed ID: 21433318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.